Aura Biosciences is a biotechnology company focused on developing cancer therapies. Its virus-like drug conjugates (VDC) technology platform is tailored to treat tumors of high unmet need in ocular and urologic oncology, with AU-011 being a VDC candidate for the treatment of primary choroidal melanoma. The company was established in 2009 and is headquartered in Cambridge, Massachusetts.